Session VI: Immune Checkpoint Inhibitors for NSCLC

Moderator(s)

• 

  Edward Garon, MD, MS

  University of California, Los Angeles

Presenter(s)

• 

  Marina Garassino, MD

  University of Chicago
• 

  Leena Gandhi, MD, PhD

  Harvard Medical School/Dana-Farber Cancer Institute

Presentations:

• 8:20 AM – 8:35 AM

  Welcome and Introduction; Pre-Session Audience Survey
  

  Chair: Edward B. Garon, MD, MS – University of California, Los Angeles
• 8:35 AM – 8:55 AM

  Basics of Immunotherapy in NSCLC
  

  Speaker: Edward B. Garon, MD, MS – University of California, Los Angeles
• 8:55 AM – 9:15 AM

  Primacy of CPIs in Front-Line Management
  

  Speaker: Marina Garassino, MD – University of Chicago
• 9:15 AM – 9:25 AM

  Debate: How to Handle PD-L1 > 50% - Use pembrolizumab + Histology Specific Chemo
  

  Debate Speaker: Leena Gandhi, MD, PhD – Harvard Medical School/Dana-Farber Cancer Institute
• 9:25 AM – 9:35 AM

  Debate: How to Handle PD-L1 > 50% - Use Pembrolizumab alone
  

  Debate Speaker: Edward B. Garon, MD, MS – University of California, Los Angeles
• 9:35 AM – 9:55 AM

  Q&A; Post-Session Audience Survey
  

  Moderator: Edward B. Garon, MD, MS – University of California, Los Angeles

  Panelist: Leena Gandhi, MD, PhD – Harvard Medical School/Dana-Farber Cancer Institute

  Panelist: Marina Garassino, MD – University of Chicago